Fig. 6: Enhancement of RT efficacy by Pt-HFn on C17 PDX tumors in vivo.

a Schematic diagram of the single-dose RT (6 Gy) treatment of mice inoculated with C17 PDX tumor subcutaneously on the right flank (PtNPs + RT, n = 6 mice; other group, n = 7 mice). b Average and c individual tumor growth curves in groups undergoing the treatment regimen depicted in a. d Kaplan–Meier survival curves of control and RT (6 Gy)-treated C17 PDX mice with or without Pt-HFn. e Schematic diagram of the single-dose RT (6 Gy) treatment of C17 PDX mice inoculated with C17 tumor subcutaneously on the right flank (n = 7 mice). f Average and g individual tumor growth curves in groups receiving the treatment regimen depicted in e. h Kaplan–Meier survival curves of control and RT (6 Gy)-treated C17 PDX mice with Pt-HFn, HFn, or CMNa. i Schematic diagram illustrating the fractionated RT (2 Gy × 5) treatment of C17 PDX-bearing mice (n = 5 mice). j Average and k individual tumor growth curves in groups receiving the treatment regimen depicted in i. l Kaplan–Meier survival curves of control and RT (2 Gy × 5)-treated C17 PDX-bearing mice receiving Pt-HFn, HFn, or CMNa. Data are shown as mean ± SEM. Ordinary two-way ANOVA with Tukey’s multiple comparisons test in b, f, and j and log-rank (Mantel–Cox) test in d, h, and l were used to calculate P values. Source data are provided as a Source Data file.